These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

220 related articles for article (PubMed ID: 25704217)

  • 1. Safety and tolerability of TRAIL receptor agonists in cancer treatment.
    Fulda S
    Eur J Clin Pharmacol; 2015 May; 71(5):525-7. PubMed ID: 25704217
    [TBL] [Abstract][Full Text] [Related]  

  • 2. TRAIL receptor signalling and modulation: Are we on the right TRAIL?
    Mahalingam D; Szegezdi E; Keane M; de Jong S; Samali A
    Cancer Treat Rev; 2009 May; 35(3):280-8. PubMed ID: 19117685
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The promise of cancer therapeutics targeting the TNF-related apoptosis-inducing ligand and TRAIL receptor pathway.
    Wang S
    Oncogene; 2008 Oct; 27(48):6207-15. PubMed ID: 18931688
    [TBL] [Abstract][Full Text] [Related]  

  • 4. TRAIL agonists on clinical trials for cancer therapy: the promises and the challenges.
    Bellail AC; Qi L; Mulligan P; Chhabra V; Hao C
    Rev Recent Clin Trials; 2009 Jan; 4(1):34-41. PubMed ID: 19149761
    [TBL] [Abstract][Full Text] [Related]  

  • 5. TRAIL as a target in anti-cancer therapy.
    Wu GS
    Cancer Lett; 2009 Nov; 285(1):1-5. PubMed ID: 19299078
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Onto better TRAILs for cancer treatment.
    de Miguel D; Lemke J; Anel A; Walczak H; Martinez-Lostao L
    Cell Death Differ; 2016 May; 23(5):733-47. PubMed ID: 26943322
    [TBL] [Abstract][Full Text] [Related]  

  • 7. TRAIL receptor signaling and therapeutics.
    Abdulghani J; El-Deiry WS
    Expert Opin Ther Targets; 2010 Oct; 14(10):1091-108. PubMed ID: 20819019
    [TBL] [Abstract][Full Text] [Related]  

  • 8. TRAIL and targeting cancer cells: between promises and obstacles.
    Limami Y; Pinon A; Riaz A; Simon A
    Cell Mol Biol (Noisy-le-grand); 2015 Oct; 61(6):33-8. PubMed ID: 26518894
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Ligand-based targeting of apoptosis in cancer: the potential of recombinant human apoptosis ligand 2/Tumor necrosis factor-related apoptosis-inducing ligand (rhApo2L/TRAIL).
    Ashkenazi A; Holland P; Eckhardt SG
    J Clin Oncol; 2008 Jul; 26(21):3621-30. PubMed ID: 18640940
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The three Rs along the TRAIL: resistance, re-sensitization and reactive oxygen species (ROS).
    Mellier G; Pervaiz S
    Free Radic Res; 2012 Aug; 46(8):996-1003. PubMed ID: 22559302
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Therapeutic targeting of CD95 and the TRAIL death receptors.
    Gerspach J; Pfizenmaier K; Wajant H
    Recent Pat Anticancer Drug Discov; 2011 Sep; 6(3):294-310. PubMed ID: 21762072
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Tumor-necrosis-factor-related apoptosis-inducing ligand (TRAIL).
    Fulda S
    Adv Exp Med Biol; 2014; 818():167-80. PubMed ID: 25001536
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Modulation of death receptor pathways in oncology.
    de Vries EG; Timmer T; Mulder NH; van Geelen CM; van der Graaf WT; Spierings DC; de Hooge MN; Gietema JA; de Jong S
    Drugs Today (Barc); 2003; 39 Suppl C():95-109. PubMed ID: 14988748
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Targeting TNF-related apoptosis-inducing ligand (TRAIL) receptor by natural products as a potential therapeutic approach for cancer therapy.
    Dai X; Zhang J; Arfuso F; Chinnathambi A; Zayed ME; Alharbi SA; Kumar AP; Ahn KS; Sethi G
    Exp Biol Med (Maywood); 2015 Jun; 240(6):760-73. PubMed ID: 25854879
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The TRAIL to cancer therapy: Hindrances and potential solutions.
    Wong SHM; Kong WY; Fang CM; Loh HS; Chuah LH; Abdullah S; Ngai SC
    Crit Rev Oncol Hematol; 2019 Nov; 143():81-94. PubMed ID: 31561055
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Progress on targeting TRAIL's receptor as antitumor strategy].
    Chen SZ
    Yao Xue Xue Bao; 2009 Dec; 44(12):1336-42. PubMed ID: 21351465
    [TBL] [Abstract][Full Text] [Related]  

  • 17. TRAIL receptor-targeted therapeutics: resistance mechanisms and strategies to avoid them.
    Thorburn A; Behbakht K; Ford H
    Drug Resist Updat; 2008; 11(1-2):17-24. PubMed ID: 18374623
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Cancer: novel therapeutic strategies that exploit the TNF-related apoptosis-inducing ligand (TRAIL)/TRAIL receptor pathway.
    Cretney E; Takeda K; Smyth MJ
    Int J Biochem Cell Biol; 2007; 39(2):280-6. PubMed ID: 17097329
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The TRAIL apoptotic pathway in cancer onset, progression and therapy.
    Johnstone RW; Frew AJ; Smyth MJ
    Nat Rev Cancer; 2008 Oct; 8(10):782-98. PubMed ID: 18813321
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Targeted induction of apoptosis in cancer management: the emerging role of tumor necrosis factor-related apoptosis-inducing ligand receptor activating agents.
    Rowinsky EK
    J Clin Oncol; 2005 Dec; 23(36):9394-407. PubMed ID: 16361639
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.